title: Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?
abstract: The febrile neutropenia episodes of hematological patients and their outcomes were evaluated with respect to fungal pathogens and antifungal therapy in this retrospective study. All patients, who were older than 14 years of age and developed at least one neutropenic episode after chemotherapy due to hematological cancer from November 2010 to November 2012, were included into the study. We retrospectively collected demographic, treatment, and survival data of 126 patients with neutropenia and their 282 febrile episodes. The mean Multinational Association for Supportive Care in Cancer score was 17.18 ± 8.27. Systemic antifungal drugs were initiated in 22 patients with 30 culture-proven invasive fungal infections (IFIs), 25 attacks of 19 patients with probable invasive pulmonary aspergillosis (IPA), 42 attacks of 38 patients with possible IPA, and 31 attacks of 30 patients with suspected IFI. Voriconazole (VOR), caspofungin and liposomal amphotericin B were used to treat 72 episodes of 65 patients, 45 episodes of 37 patients and 34 episodes of 32 patients as a first-line therapy, respectively. Unfavorable conditions of our hematology ward are thought to increase the number of cases with invasive pulmonary aspergillosis and VOR use. It should be taken into consideration that increased systemic and per oral VOR usage predisposes patients to colonization and infection with azole-resistant fungal strains. Catheters should be removed in cases where patients' conditions are convenient to remove it. Acute myeloblastic leukemia cases that are more likely to develop invasive fungal infections should be monitored closely for early diagnosis and timely initiation of antifungal drugs which directly correlates with survival rates.
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Habip
authors.initials: H
authors.lastname: Gedik
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Funda
authors.initials: F
authors.lastname: Şimşek
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Taner
authors.initials: T
authors.lastname: Yıldırmak
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Arzu
authors.initials: A
authors.lastname: Kantürk
authors.affiliation: Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Arıca
authors.affiliation: Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Demet
authors.initials: D
authors.lastname: Aydın
authors.affiliation: Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Naciye
authors.initials: N
authors.lastname: Demirel
authors.affiliation: Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey.
authors.forename: Osman
authors.initials: O
authors.lastname: Yokuş
keywords: Antifungal treatment; Febrile neutropenia; Fungemia; Hematological patients; Invasive fungal infection
references.citation: Clin Infect Dis. 2002 Mar 15;34(6):730-51
references.pmid: 11850858
references.citation: Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67
references.pmid: 23137137
references.citation: Med Mycol. 2012 Jan;50(1):50-5
references.pmid: 21696259
references.citation: Cancer. 2007 Dec 15;110(12):2740-6
references.pmid: 17941026
references.citation: Diagn Microbiol Infect Dis. 1992 Jan;15(1):21-34
references.pmid: 1309690
references.citation: Ann Intern Med. 1977 May;86(5):539-43
references.pmid: 851301
references.citation: Clin Infect Dis. 2005 Apr 1;40 Suppl 4:S240-5
references.pmid: 15768329
references.citation: Clin Infect Dis. 2000 Nov;31(5):1155-63
references.pmid: 11073745
references.citation: J Antimicrob Chemother. 2012 Sep;67(9):2268-73
references.pmid: 22653819
references.citation: Emerg Infect Dis. 2011 Oct;17(10):1846-54
references.pmid: 22000354
references.citation: Kidney Int. 2001 Oct;60(4):1452-9
references.pmid: 11576359
references.citation: Int J Mol Sci. 2012;13(1):774-787
references.pmid: 22312285
references.citation: Ann N Y Acad Sci. 2008 Sep;1138:329-50
references.pmid: 18837909
references.citation: J Antimicrob Chemother. 2012 Oct;67(10):2506-13
references.pmid: 22778159
references.citation: Lancet Infect Dis. 2011 Feb;11(2):142-51
references.pmid: 21272794
references.citation: Expert Opin Pharmacother. 2012 Aug;13(12):1695-705
references.pmid: 22716311
references.citation: Antimicrob Agents Chemother. 1995 Sep;39(9):1907-12
references.pmid: 8540690
references.citation: J Chemother. 2011 Apr;23(2):92-6
references.pmid: 21571625
references.citation: J Chemother. 2012 Dec;24(6):311-27
references.pmid: 23174096
references.citation: Clin Infect Dis. 2010 Aug 1;51(3):295-303
references.pmid: 20578829
references.citation: Int J Hematol. 2008 Dec;88(5):508-515
references.pmid: 18982251
references.citation: Clin Infect Dis. 2011 Feb 15;52(4):427-31
references.pmid: 21205990
references.citation: J Clin Microbiol. 2004 Jul;42(7):3142-6
references.pmid: 15243073
references.citation: Clin Infect Dis. 2002 Jan 1;34(1):7-14
references.pmid: 11731939
references.citation: Ann Hematol. 2002 May;81(5):233-43
references.pmid: 12029531
references.citation: Infect Control Hosp Epidemiol. 2005 Jun;26(6):540-7
references.pmid: 16018429
references.citation: Clin Infect Dis. 2008 Feb 1;46(3):327-60
references.pmid: 18177225
references.citation: J Clin Oncol. 1996 Feb;14(2):636-43
references.pmid: 8636781
references.citation: N Engl J Med. 2007 Jan 25;356(4):409-11
references.pmid: 17251538
references.citation: J Clin Oncol. 2001 Jan 1;19(1):253-9
references.pmid: 11134220
references.citation: J Med Microbiol. 2007 Feb;56(Pt 2):255-259
references.pmid: 17244809
references.citation: N Engl J Med. 1999 Mar 11;340(10):764-71
references.pmid: 10072411
references.citation: Clin Infect Dis. 2009 Jul 1;49(1):1-45
references.pmid: 19489710
references.citation: Clin Infect Dis. 2004 Sep 1;39(5):743-6
references.pmid: 15356792
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v252-6
references.pmid: 20555092
references.citation: Br J Haematol. 2004 Sep;126(6):852-60
references.pmid: 15352990
references.citation: Mediterr J Hematol Infect Dis. 2012;4(1):e2012011
references.pmid: 22348193